Ondansetron Hikma

Ondansetron, the active ingredient in Ondansetron Hikma, is a 5-HT3 receptor antagonist presented as a 4 mg tablet for oral use. It helps prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery in adult and pediatric patients. GNH USA supplies Ondansetron Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Ondansetron Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron Hikma is a selective 5‑HT3 receptor antagonist used to manage nausea and vomiting across several clinical pathways.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting: helps control symptoms during and after radiotherapy. - Post‑operative nausea and vomiting: decreases the incidence of nausea and vomiting after surgical procedures. - Pregnancy‑related hyperemesis gravidarum (off‑label in some regions): may be considered when conventional therapy fails.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement reduction. - Diarrhoea: loose stools in a minority of patients. - Fatigue: general tiredness reported. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - QT prolongation: cardiac rhythm changes requiring ECG monitoring. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic enzyme elevation: abnormal liver function tests. - Vision changes: blurred vision or visual disturbances.

When prescribing Ondansetron Hikma, consider the following precautions:

- Cardiac monitoring: assess baseline ECG in patients with known cardiac disease. - Electrolyte balance: correct hypokalaemia or hypomagnesaemia before use. - Drug interactions: review concomitant serotonergic medications. - Pregnancy and lactation: weigh benefits against potential risks. - Renal or hepatic impairment: dose adjustment may be required. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines; careful review is advised.

Major Interactions (Avoid): - Apomorphine: can cause profound hypotension and loss of consciousness. - Certain anti‑arrhythmic drugs (e.g., quinidine, amiodarone): increase risk of QT prolongation.

Moderate Interactions (Monitor Closely): - Serotonergic agents (e.g., SSRIs, MAOIs, tramadol): may increase risk of serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): raise ondansetron plasma levels. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): modestly increase exposure. - Oral contraceptives: may reduce hormonal efficacy. - Antacids containing aluminium or magnesium: may lower oral absorption.